Launched in 2005, the Huningue production facility is a global leader in monoclonal antibodies manufacturing. More than 700 highly qualified men and women work here producing innovative, complex biopharmaceuticals across a diversity of therapeutic areas, including dermatology, immunology, and respiratory diseases. These treatments can significantly improve the daily lives of patients.

**OUR AMBITIONS**

- **To guarantee clinical and commercial production** of pharmaceuticals for patients around the world, with the highest levels of quality
- **To build and encourage a culture** in which each employee feels comfortable, safe, empowered, and proud to be part of ‘Made in Huningue’

“ At Novartis, our mission is to provide patients worldwide with innovative medicine that give them hope for the future. To achieve these ambitions we continually invest to strengthen our production capacity and modernize our facilities. In addition to our state of the art facilities, our ability to manufacture products to uncompromising levels of quality and safety relies on the commitment and passion of the teams who drive innovation forward on an everyday basis for the benefit of patients.”

Paula Rosa – Huningue Site Head

**KEY DATA**

- **4 BIOPHARMACEUTICALS** manufactured using cell culture technology
- **3 PRODUCTION UNITS** working 24/7
- **150 MILLION EUROS** invested to launch a new production line in 2020
- **8 BIOREACTORS** of cell culture of 15 000L each
- **18+ NATIONALITIES** represented in this facility
- **2025 CARBON NEUTRAL**